FVIII/vWF-immunodepleted plasma (substrate plasma) was purchased from Precision Biologic (Dartmouth, Canada). the activity of rFVIII (FVIIc) decreased to 50%. This inhibitory effect of vWF decreased with decreasing rFVIII concentration in SP and became negligible at rFVIII 10% (150 pM). The FVIIIc of 1 1.5 nM FVIII in two products formulated with vWF (Immunate and Hemofil M) was not affected by the addition of exogenous vWF to the SP, whereas the FVIIIc of the B-domainless rFVIII product ReFacto was decreased 64% by the addition of vWF. In the synthetic coagulation proteome brought on with 5 pM tissue factor, vWF had no effect on thrombin generation. == Conclusions == vWF has an inhibitory effect on the measurement of FVIII clotting activity. This effect depends upon the structure and formulation of the FVIII product. Keywords:factor VIII, von Willebrand factor, clotting activity, factor VIII products, tissue factor, synthetic coagulation proteome == Introduction == Factor (F) VIII is usually a nonenzymatic procofactor, which upon activation is usually converted to its active form FVIIIa. FVIIIa binds FIXa and forms a complex enzyme around the membrane surface, intrinsic FXase, which converts zymogen FX to serine protease FXa(1). FVIII circulatesin vivoas a heterodimer consisting of a heterogenous NH2-terminal heavy chain and a COOH-terminal light chain associated in a divalent metal ion-dependent manner(2). FVIII forms a complex through the light chain with von Willebrand factor (vWF), which protects FVIII from proteolysis and concentrates FVIII at the site of active hemostasis(3;4). Upon activation, the light chain of FVIII dissociates from vWF, and the generated FVIIIa is capable to bind FIXa and transiently express cofactor activity(5). It has been shown in previous publications that vWF inhibits FVIII activation by FXa(69). No inhibition of FVIII activation and activity by vWF was observed when thrombin was used as an activator(6;10). All of these activation experiments were performed using purified proteins, supraphysiologic concentrations of FVIII and a Mouse monoclonal antibody to Albumin. Albumin is a soluble,monomeric protein which comprises about one-half of the blood serumprotein.Albumin functions primarily as a carrier protein for steroids,fatty acids,and thyroidhormones and plays a role in stabilizing extracellular fluid volume.Albumin is a globularunglycosylated serum protein of molecular weight 65,000.Albumin is synthesized in the liver aspreproalbumin which has an N-terminal peptide that is removed before the nascent protein isreleased from the rough endoplasmic reticulum.The product, proalbumin,is in turn cleaved in theGolgi vesicles to produce the secreted albumin.[provided by RefSeq,Jul 2008] preformed activator, i.e. FXa and thrombin at the concentrations selected somewhat randomly. However, it is not clear what effect on FVIII activation/activity vWF has at physiologic conditions when both potential FVIII activators are formed at Daphnetin the Daphnetin same time and both proteins (FVIII and vWF) are present at physiologically relevant concentrations. In this study, we evaluate the Daphnetin influence of vWF on FVIII activity in the APTT clotting assay using FVIII/vWF-depleted substrate plasma and in the synthetic coagulation proteome brought on with TF(11;12). == Materials and methods == == Materials == All FVIII products were provided by Baxter Health Care Corp. (Duarte, CA). Albumin-free recombinant FVIII (rFVIII) produced in CHO cells was used as the calibrator (standard) in all assays. The concentration of this product (0.62 mg/ml) was established by the absorbance at 280 nm using an extinction coefficient E0.1%value of 1 1.3(13). Three lots of purified human vWF and polyclonal goat anti-vWF antibody were provided as gifts by Dr. R. Jenny from Haematologic Technologies, Inc (Essex Junction, VT). FVIII/vWF-immunodepleted plasma (substrate plasma) was purchased from Precision Biologic (Dartmouth, Canada). Congenital FVIII-deficient plasma (lot #GK 884-17c1) was purchased from George King Bio Daphnetin Medical, Inc; Overland Park, KS). The APTT reagent was purchased from Trinity Biotech PLC Bray (Wicklow, Ireland). 10-donor normal plasma, biotin-labeled monoclonal anti-FVIII heavy-chain antibody 24 (-FVIII-24) and monoclonal anti-vWF antibody (-vWF-99) were produced in house. Monoclonal anti-FVIII light-chain antibody 68 (-FVIII-68) was produced by Dr. D. Fass. HRP-streptavidin was purchased from Sigma (St. Louis, MO), chromogenic substrate from KPL (Gaitherburg, MD) and HRP-goat anti-mouse Ig was purchased from Amersham Life Sciences (Arlington Heights, IL). Human coagulation factors VII, X, IX, and prothrombin were isolated from fresh frozen plasma using the methods of Bajajet al.(14) and FXI using the monoclonal anti-FXI antibody -FXI-2. All preparations were purged of trace contaminants and traces of active enzymes as described(15). Human FV and AT-III were isolated from freshly frozen citrated plasma(16;17). Citrated plasma for protein purification was purchased from Haematologic Technologies, Inc. rTF1-242(expressed inE. coli) was provided as a gift from Drs. Shu Len Liu and Roger Lundblad (Baxter Healthcare Corp). Human rFVIIa was provided as a gift by Dr. Ula Hedner (Novo Nordisk, Denmark). Full-length recombinant tissue factor pathway inhibitor (TFPI) was a gift from Dr. S. Hardy (Chiron Corp, Emeryville, CA). 1,2-Dioleolyl-sn-Glycero-3-Phospho-L-Serine (PS) and 1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (PC) were purchased from Avanti Polar Lipids, Inc (Alabaster, AL). Ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) and -mercaptoethanol were purchased from Sigma (St Louis, MO). Phospholipid vesicles (PCPS) composed of 25% PS and 75% PC were prepared as described(18). TF was relipidated into PCPS vesicles (molar ratio 1:5000) as described(19). Spectrozyme TH was purchased from American Diagnostica, Inc (Greenwich, CT). == ELISA == == FVIII == The assay utilized a double-sandwich format using -FVIII-68.